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Introduction: Renal ischemia reperfusion injury is one of the main causes of acute renal failure, which is 
associated with high mortality. Tissue damage caused by ischemia-reperfusion occurs due to the release of oxygen 
free radicals. Type I angiotensin receptor antagonists such as valsartan can be useful in the treatment of chronic 
kidney disease and hypertension. 
Objectives: We aimed to evaluate the protective effect of valsartan against renal ischemia reperfusion via 
antioxidant property and nitric oxide (NO) signaling pathway.
Materials and Methods: Fifty male Wistar rats (220±10 g) were randomly divided into five groups as follows: 
Group 1; healthy rats without ischemia-reperfusion (control group). Group 2; rats with ischemia reperfusion (IR) 
(IR control group). Group 3; rats with IR which received 30 mg/kg valsartan orally. Group 4; rats with IR which 
received 30 mg/kg valsartan together with 40 mg/kg L-NAME. Group 5; rats with IR which received 30 mg/kg 
valsartan together with 40 mg/kg L-arginine. To induce ischemia-reperfusion, rats were anesthetized with thiopental 
and underwent surgery. Then, we induced ischemia with blocking blood vessels for 45 minutes by clamping. 
Biochemical parameters including urea and creatinine were measured using commercial kits. Oxidative stress 
and inflammatory parameters were measured by ELISA method. Renal tissues were stained with hematoxylin and 
eosin. Finally, the Kolmogorov-Smirnov test was used to determine the normal distribution of data.
Results: The findings of this study indicated that treatment with valsartan and valsartan plus L-arginine leads to 
significant decrease in the serum levels of creatinine, urea, and albumin/creatinine, malondialdehyde (MDA), 
interleukin-6 (IL-6) and tumor necrosis factor-alpha (TNF-alpha) in contrast to IR control group which has 
increased level of these parameters. On the other hand, treatment with valsartan and valsartan plus L-arginine lead 
to increase in the serum levels of glutathione peroxidase (GPX), in contrast to ischemia reperfusion control group.
Conclusion: Our data revealed that valsartan as a type I angiotensin receptor antagonist could decrease oxidative 
stress and inflammation due to renal ischemia reperfusion injury. Hence, valsartan could propose as a therapeutic 
agent for kidney diseases such as renal ischemia-reperfusion injury regarded to these renoprotective effects.
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The kidneys play a key role in the filtration, 
metabolism and elimination of xenobiotics or 
their metabolic products (1). Renal ischemia 
reperfusion injury is one of the main causes 
of acute renal failure, which is associated with 
high mortality. It is also one of the reasons 
for delayed kidney transplantation function 
and the increase of acute or chronic renal 
transplant rejection in kidney transplantation 
(2). Renal ischemia reperfusion injury not only 
is an inevitable result of renal transplantation, 
but also is observable in other conditions such 
Key point 
In an experimental study we found that valsartan as 
a type I angiotensin receptor antagonist drugs could 
decrease oxidative stress and inflammation due to 
renal ischemia-reperfusion injury. Hence, valsartan 
could be proposed as a therapeutic agent for kidney 
diseases such as renal ischemia-reperfusion injury 
regarded to these renoprotective effects.
as myocardial infarction, shock and systemic 
blood pressure reduction (3). During 
ischemia-reperfusion, the morphological 
and functional damage induced during the 
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ischemic period is exacerbated during reperfusion. Tissue 
damage caused by ischemia-reperfusion occurs due to the 
release of oxygen free radicals, imbalance in intracellular 
and mitochondrial calcium regulation, microscopic 
vascular dysfunction, and complete failure to return blood 
flow to microscopic vessels, which intensify inflammatory 
response with immune cell infiltration (4,5). Reactive 
oxygen species are produced at high concentrations after 
the re-establishment of blood flow in ischemic tissues (6). 
In normal conditions, the antioxidant enzymes neutralize 
the effects of free oxygen radicals in the cells. However, 
during reperfusion, the protective ability of these enzymes 
is reduced due to the rapid production of free oxygen 
species, resulting in apoptosis and cell death. Therefore, 
the reduction of oxidative stress with pharmacological 
approaches is a desirable goal for treatment to slow down 
the damage of ischemia-reperfusion.
Type I angiotensin receptor antagonists such as losartan 
and valsartan are used to treat high blood pressure and 
control congestive heart failure (7). 
Objectives
Various studies have shown that angiotensin receptor 
antagonists have protective effects in some tissues 
following various injuries such as renal injuries (8). As 
it has been shown, angiotensin receptor antagonists can 
be useful in preventing lesions after cardiac and brain 
strokes (9). Additionally, the drugs present in this group 
can show anti-platelet, anti-diabetic, vascular antiplatelet, 
antihypertensive effects, and also atrial antifibrillatory 
(10). Also, in patients with chronic kidney disease and 
hypertension, after the administration of these drugs, the 
severity of renal impairment has been reduced (11). Hence, 
we decided to evaluate the protective effect of valsartan 
against renal ischemia reperfusion via antioxidant and 
anti-inflammatory property and NO signaling pathway.
Materials and Methods 
Animals and study design
Fifty male Wistar rats (220±10 g) in the faculty of 
pharmacy, Lorestan Medical Science University were 
examined in this study. All animals were housed in normal 
laboratory condition (temperature: 21-25◦C and light 
cycle: 12 h dark- 12 h light).
Then, all rats randomly assigned into five groups;
Group 1; normal rats (control group).
Group 2; ischemic/ reperfusion (IR) Rats 
Group 3; IR rats + valsartan (30 mg/kg, gavage)
Group 4; IR rats + valsartan (30 mg/kg, gavage) + L-NAME 
(40 mg/kg, intraperitoneal; IP).
Group 5; IR rats + valsartan (30 mg/kg, gavage) + 
L-arginine (40 mg/kg, IP).
Surgical procedure
To induce of ischemia-reperfusion, a single injection 
of thiopental (60 mg/kg, IP) was administered. After 
anesthesia, the kidney was exposed. Next, we carefully 
clamping around blood vessels for 45 minutes. After 45 
minutes, for reperfusion removed the clamps around 
blood vessels. Animals killed 3 days after the operation.
Biochemical and biomarker parameters measurement
In the last days, blood samples were collected and it 
centrifuged at 2500 rpm for 20 minutes to separation of 
serum. The serum was used for assessing the levels of 
urea, creatinine, malondialdehyde (MDA), glutathione 
peroxidase (GPx), interleukin-6 (IL-6) and tumor necrosis 
factor-alpha (TNF-alpha) by an auto-analyzer (12).
Renal histologic analysis
In the last day, the right kidney was exposed and separated. 
The specimen was stained with hematoxylin and eosin and 
was scored the tubular necrosis and eosinophilic casts (13).
Ethical issues
The research and the protocol of this study was in 
accordance with the guidelines of animal studies and was 
approved by Ethics Committee of Lorestan University of 
Medical (IR.LUMS.REC.1397.094). Accordingly, we tried 
to conduct the guidelines related to animal experiments, 
approved by the United States National Institutes of Health 
(NIH, 1978). 
Statistical analysis
Data analysis was done using GraphPad Prism version 5.0 
software. One-way ANOVA analysis followed by post hoc 
Dunnett test was used. The results presented by mean ± 
SD and the significance level will be below 0.05 (P<0.05). 
Results
Effect of valsartan on serum level of creatinine
An increased level of creatinine was observed in the 
IR control group in comparison to the healthy control 
group. However, valsartan and valsartan plus L-arginine 
treatment dropped the level of creatinine compared to 
the other groups. Figure 1 shows the creatinine level in 
different groups (P<0.05).
Effect of valsartan on level of albumin/creatinine
As shown in Figure 2, an significant elevation in the level 
of albumin/creatinine in the IR control group compared 
to the control group was observed. On the other hand, 
the levels of albumin/creatinine significantly reduced in 
treated groups especially in valsartan and valsartan plus 
L-arginine compared to untreated groups and IR control 
group (P<0.05).
Effect of valsartan on serum level of urea
According to Figure 3, the level of urea increased in the 
IR control group more than the control group. Moreover, 
it depressed significantly in valsartan and valsartan plus 
L-arginine treated groups (P<0.05).
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to the control group. Moreover, valsartan and valsartan 
plus L-arginine caused reduction in the level of IL-6, as 
shown in Figure 7.
Discussion
Renal ischemia reperfusion injury is a pathologic 
Effect of valsartan on serum level of MDA
According to Figure 4, the serum level of MDA elevated 
significantly in the IR control group compared to the 
control group. However, it depressed significantly in 
valsartan and valsartan plus L-arginine treated groups 
compared to other groups.
Effect of valsartan on serum level of GPX
The level of GPX reduced in the IR group in comparison 
with the control group. Moreover, valsartan and valsartan 
plus L-arginine caused elevation in the level of GPX, as 
shown in Figure 5.
Effect of valsartan on serum level of TNF-alpha
The level of TNF-alpha increased in the IR group in 
comparison with the control group. Moreover, valsartan 
and valsartan plus L-arginine caused reduction in the level 
of TNF-alpha, as shown in Figure 6.
Effect of valsartan on serum level of IL-6
The level of IL-6 increased in the IR group in comparison 
Figure 1. The creatinine level in different groups.
Figure 2. The level of albumin/creatinine in different groups.
Figure 4. The level of MDA in different groups.
Figure 3. The level of urea in different groups.
Figure 6. The level of TNF-alpha in different groups.
Figure 7. The level of IL-6 in different groups.
Figure 5. The level of GPx in different groups.
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condition which causes disruption of blood supply in 
kidneys. Stopping the blood supply to the kidney is called 
ischemic condition (5). This condition and subsequent 
reestablishment of blood flow leads to production of 
reactive oxygen species and activation of inflammatory 
mediators which causes damage to kidneys. Therefore, the 
administration of several drug compounds can involve in 
reduction of the oxidative stress and inflammation caused 
by renal ischemia reperfusion injury (14). In this study, we 
evaluated the effects of valsartan as an antihypertension 
drug and renin inhibitor in the treatment of renal ischemia 
reperfusion injury. The results of our study showed that the 
serum level of creatinine, urea, MDA, albumin/creatinine, 
TNF-alpha and IL-6 decreased significantly after valsartan 
and valsartan plus L-arginine treatment compared to IR 
control group. Vice versa, the serum level of GPX increased 
significantly after valsartan and valsartan plus L-arginine 
treatment compared to IR control group. We also evaluated 
the oxidative stress parameters including the serum levels 
of MDA and GPX in different groups. Our results indicated 
that the serum levels of MDA decreased significantly after 
treatment with valsartan. On the other hand, treatment 
with valsartan caused a significant increase in the serum 
levels of GPX. 
The serum levels of creatinine, urea and albumin/creatinine 
decreased significantly after valsartan and valsartan plus 
L-arginine treatment compared to IR control group. 
Effects of valsartan have been evaluated in patients with 
chronic kidney disease. The results of their study showed 
that the serum level of creatinine in patients decreased 
significantly after treatment with valsartan (15). A recent 
study evaluated the effect of valsartan on chronic kidney 
disease in patients. The authors of this study concluded 
that pretreatment with valsartan decreased serum levels of 
blood urea nitrogen and creatinine 90 days after treatment, 
however, it was not significant (16). The effect of valsartan 
was also evaluated on serum levels of urea and creatinine 
in doxorubicin-induced renal toxicity in rats. Their results 
indicated that serum levels of urea and creatinine elevated 
significantly following doxorubicin treatment. Vice versa, 
treatment of rats with valsartan (10, 20 mg/kg) especially 
20 mg/kg leads to significant depression in the serum 
levels of urea and creatinine (17).
The anti-inflammatory effects of valsartan were also 
assessed using measuring the serum levels of TNF-alpha 
and IL-6 in different groups. Our results showed that an 
increase in inflammatory mediators such as TNF-alpha and 
IL-6 was induced after the development of renal ischemia 
reperfusion injury. However, valsartan treatment could 
affect inflammation caused by renal ischemia-reperfusion 
injury through reducing the serum levels of TNF-alpha and 
IL-6. Wang et al, in a study on the ameliorative impact of 
valsartan on podocyte damage in rats with diabetic kidney 
disease, showed anti-inflammatory effects of valsartan in 
diabetic nephropathy. The results of their study indicated 
that the concentrations of inflammatory mediators such 
as IL-β, TNF-α and IL-6 increased significantly in the 
diabetic nephropathy group. However, treatment by 
valsartan could decrease significantly the levels of IL-β, 
TNF-α and IL-6 (18).
Conclusion
In conclusion, different natural compounds and 
chemical drugs are used for protection of kidneys against 
various types of renal injuries such as renal ischemia-
reperfusion injury. Our data revealed that valsartan as 
a type I angiotensin receptor antagonist drugs could 
decrease oxidative stress and inflammation due to renal 
ischemia-reperfusion injury. Hence, valsartan could 
propose as a therapeutic agent for kidney diseases such 
as renal ischemia-reperfusion injury regarded to these 
renoprotective effects.
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